Table 1.
Demographic and clinical characteristics of analysis sample by concurrent albuminuria status.
| Variable | All Subjects (n=436) | Albuminuria Group | P Value | ||
|---|---|---|---|---|---|
|
| |||||
| Normal (n=341) | Micro (n=50) | Macro (n=45) | |||
| Age (yrs) | 40.2 ± 7.1 | 40.4 ± 6.9 | 39.6 ± 7.7 | 39.5 ± 8.2 | 0.764 |
| Male % (n) | 64.7 (282) | 62.8 (214) | 66.0 (33) | 77.8 (35) | 0.137 |
| Intensive Treatment % (n) | 47.9 (209) | 54.0 (184) | 30.0 (15) | 22.2 (10) | <0.001 |
| Primary Prevention Cohort % (n) | 37.6 (164) | 39.9 (136) | 30.0 (15) | 28.9 (13) | 0.179 |
| Duration of T1DM (yrs) | 19.0 ± 4.4 | 19.0 ± 4.5 | 19.1 ± 4.5 | 19.5 ± 4.1 | 0.591 |
| BMI (kg/m2) | 26.6 ± 3.8 | 26.5 ± 3.7 | 26.9 ± 4.0 | 26.4 ± 4.1 | 0.609 |
| Waist to Hip Ratio | 0.86 ± 0.09 | 0.85 ± 0.09 | 0.86 ± 0.10 | 0.88 ± 0.06 | 0.080 |
| Systolic BP (mm Hg) | 75.3 ± 9.5 | 118.2 ± 12.2 | 124.3 ± 14.2 | 137.0 ± 21.7 | <0.001 |
| Diastolic BP (mm Hg) | 120.9 ± 14.9 | 73.9 ± 8.7 | 79.6 ± 10.2 | 81.2 ± 10.3 | <0.001 |
| Hypertension % (n) | 28.0 (253) | 66.0 (225) | 44.0 (22) | 13.3 (6) | <0.001 |
| Smoker % (n) | 19.3 (84) | 16.1 (55) | 30.0 (15) | 31.1 (14) | 0.007 |
| Total Cholesterol (mg/dl) | 191.3 ± 36.3 | 188.6 ± 35.8 | 188.1 ± 30.3 | 212.8 ± 39.5 | <0.001 |
| HDL Cholesterol (mg/dl) | 54.6 ± 14.5 | 55.0 ± 14.3 | 52.5 ± 15.3 | 54.2 ± 15.2 | 0.352 |
| LDL Cholesterol (mg/dl) | 117.2 ± 30.3 | 115.4 ± 30.1 | 115.7 ± 29.2 | 130.6 ± 30.9 | 0.004 |
| Triglycerides (mg/dl)* | 72 (53-114) | 66.0 (50-100) | 89.0 (58-130) | 122 (81-165) | <0.001 |
| AER (mg/day) (DCCT Baseline)* | 12.2 (7.2-21.6) | 11.5 (7.2-18.7) | 16.6 (8.6-28.8) | 17.3 (8.6-27.4) | 0.002 |
| AER (mg/day) (Current)* | 11.5 (7.2-30.2) | 8.7 (5.8-15.8) | 127 (68-203) | 720 (449-1935) | <0.001 |
| HbA1c % (Current) | 8.31 ± 1.37 | 8.12 ± 1.30 | 9.03 ± 1.45 | 8.88 ±1.44 | <0.001 |
| HbA1C % (Study Mean) | 8.29 ±1.50 | 7.96 ±1.35 | 9.09 ±1.48 | 9.86 ±1.35 | <0.001 |
| Gluc. Disp. Rate (mg.kg-1.min-1) | 7.72 ± 2.40 | 8.15 ± 2.31 | 6.77 ± 2.38 | 5.67 ±1.54 | <0.001 |
| ETDRS Score (DCCT Baseline)* | 2.0 (1.0-3.0) | 2.0 (1.0-3.0) | 3.0 (1.0-4.0) | 3.0 (1.0-4.0) | 0.008 |
| ETDRS Score (Concurrent)* | 4.0 (3.0-7.0) | 3.0 (3.0-5.0) | 8.0 (4.0-13.0) | 7.5 (5.0-14.0) | <0.001 |
| Standard Creatinine clearance (mL/sec) | 115.7 ± 24.9 | 117.1 ± 21.3 | 120.9 ± 27.0 | 99.9 ± 39.2 | 0.004 |
| Use of ACE/ARB drugs % (n) | 17.7 (77) | 10.3 (35) | 30.0 (15) | 60.0 (27) | <0.001 |
| Use of lipid-lowering drugs % (n) | 6.0 (26) | 4.4 (15) | 8.0 (4) | 15.6 (7) | 0.011 |
*
Means ± SD or Median (IQR).
P < 0.05 shown in boldface.